idiopathic pulmonary fibrosis Archives
New target for lung fibrosis
Oct. 20, 2022—Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.
VUMC and TGen receive $6.1 million in grants to study deadly lung disease
Mar. 27, 2019—Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.
Lung diseases share molecular signature
Apr. 5, 2018—Lung diseases of infancy and aging share a molecular signature, pointing to a potential target for treatment and prevention.
Study tracks therapy to slow idiopathic pulmonary fibrosis
Feb. 1, 2018—Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.
Major grant enhances pulmonary fibrosis research
Aug. 18, 2016—Vanderbilt University Medical Center (VUMC) has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF).
New drugs approved to fight idiopathic pulmonary fibrosis
Jan. 15, 2015—The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).
Lung damage protector
Apr. 12, 2013—Targeting repair pathways in the lung’s air sacs may be a valuable therapeutic direction for pulmonary fibrosis – the scarring of lung tissue.
Study examines sleep apnea’s role in lung diseases
Apr. 13, 2012—Vanderbilt’s idiopathic pulmonary fibrosis research group is embarking on a study to determine the prevalence of sleep apnea in people with other interstitial lung diseases.
Lung disorder drug regimen found harmful
Oct. 31, 2011—Longtime treatment for IPF ineffective and even dangerous.
